CD8A and neoplasm: Also, the number of tumor-infiltrating cytotoxic CD8+ T cells was significantly higher in VALO-mD901-OVA-treated tumors compared to mock- or PeptiCRAd Ad5/3-D24-OVA-treated tumors.